These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 17140033)
1. [Endothelial dysfunction: mechanisms of development and therapeutic options]. Pesić S; Radenković M; Grbović L Med Pregl; 2006; 59(7-8):335-41. PubMed ID: 17140033 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Cooke JP Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-45-51. PubMed ID: 9422852 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors]. Tschudi MR; Noll G; Lüscher TP Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890 [TBL] [Abstract][Full Text] [Related]
11. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. Lüscher TF; Spieker LE; Noll G; Cosentino F J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S3-11. PubMed ID: 11811390 [TBL] [Abstract][Full Text] [Related]
12. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Landmesser U; Hornig B; Drexler H Semin Thromb Hemost; 2000; 26(5):529-37. PubMed ID: 11129409 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic options for improvement of myocardial perfusion in coronary atherosclerosis]. Schächinger V Herz; 1998 Mar; 23(2):116-29. PubMed ID: 9592707 [TBL] [Abstract][Full Text] [Related]
14. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT; Lüscher TF Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Jamwal S; Sharma S Inflamm Res; 2018 May; 67(5):391-405. PubMed ID: 29372262 [TBL] [Abstract][Full Text] [Related]
16. Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications. Zeiher AM; Schächinger V Z Kardiol; 1994; 83 Suppl 4():7-14. PubMed ID: 7856284 [TBL] [Abstract][Full Text] [Related]
17. The physiology and pathophysiology of the nitric oxide/superoxide system. Münzel T; Heitzer T; Harrison DG Herz; 1997 Jun; 22(3):158-72. PubMed ID: 9232165 [TBL] [Abstract][Full Text] [Related]
18. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Rosenson RS Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000 [TBL] [Abstract][Full Text] [Related]
19. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. Higashi Y Int J Urol; 2017 Jun; 24(6):412-424. PubMed ID: 28332240 [TBL] [Abstract][Full Text] [Related]
20. Nitric oxide-mediated endothelial dysfunction--is there need to treat? Tiefenbacher CP; Kreuzer J Curr Vasc Pharmacol; 2003 Jun; 1(2):123-33. PubMed ID: 15320839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]